康柏西普联合激光治疗视网膜静脉阻塞继发黄斑水肿
作者:
作者单位:

作者简介:

通讯作者:

中图分类号:

基金项目:


Clinical observation of Conbercept intravitreal injection combined with retinal laser photocoagulation therapy on macular edema secondary to retinal vein occlusion
Author:
Affiliation:

Fund Project:

  • 摘要
  • |
  • 图/表
  • |
  • 访问统计
  • |
  • 参考文献
  • |
  • 相似文献
  • |
  • 引证文献
  • |
  • 资源附件
  • |
  • 文章评论
    摘要:

    目的:对比研究玻璃体腔注射康柏西普联合激光治疗与单纯激光治疗对视网膜静脉阻塞(retinal vein occlusion,RVO)继发黄斑水肿(macular edema,ME)的临床疗效。

    方法:选取2014-10/2015-03我院临床检查确诊的RVO继发ME的患者48例53眼进行回顾性分析。其中玻璃体腔内注射康柏西普+激光治疗者28例31眼,为A组; 单纯激光治疗者20例22眼,为B组。观察治疗前和治疗后1wk,3mo最佳矫正视力(best corrected visual acuity,BCVA)及黄斑中心凹视网膜厚度(central macular thickness,CMT)的变化。

    结果:随诊3mo,治疗后1wk时,A组和B组的平均BCVA分别是0.44±0.25、0.56±0.24; 平均CMT分别是330.50±121.71、354.67±102.79μm,两组患者BCVA和CMT较治疗前差异有统计学意义(P<0.05); 而术后两组组间比较,差异无统计学意义(P>0.05)。在治疗后3mo时,A组和B组的平均BCVA分别是0.24±0.18、0.39±0.20; 平均CMT分别是252.62±83.01、332.67±102.33μm,两组患者与治疗前比较、两组组间比较,差异均有统计学意义(P<0.05),且A组优于B组。

    结论:玻璃体腔注射康柏西普联合激光和单纯激光治疗RVO继发性ME均有效,ME明显减轻,视力稳定并提高。但对于水肿严重的患者,玻璃体腔注射康柏西普先减轻视网膜水肿,再联合激光治疗疗效肯定,优于单纯激光治疗。

    Abstract:

    AIM:To study the efficacy of conbercept intravitreal injection combined with retinal laser photocoagulation therapy and simple laser photocoagulation therapy on macular edema(ME)secondary to retinal vein occlusion(RVO).

    METHODS: Forty-eight patients(53 eyes)with macular edema secondary to retinal vein occlusion diagnosed by clinical examination from October 2014 to March 2015 were retrospectively analyzed. Among them, 28 patients(31 eyes)were treated with conbercept intravitreal injection combined with retinal laser photocoagulation, which was defined as Group A. And simple laser group contained 20 patients(22 eyes), which was defined as Group B. The clinical data including the patients' best-corrected visual acuity(BCVA)and central retinal thickness(CMT)before treatment and 1wk and 3mo after treatment were observed.

    RESULTS: Followed up for 3mo, the average BCVA values of A and B were 0.44±0.25,0.56±0.24, respectively and the average CMT were 330.50±121.71, 354.67±102.79μm at first week of treatment. There was no significant difference in BCVA and CMT of Group A compared with Group B. There was statistically significant in BCVA and CMT of Group A and Group B compared with before treatment(P<0.05). The average BCVA values of A and B were 0.24±0.18, 0.39±0.20, respectively and the average CMT were 252.62±83.01, 332.67±102.33μm at third month of treatment. There were statistically significant differences between the two groups and compared with before treatment(P<0.05), and Group A was superior to Group B.

    CONCLUSION: Conbercept intravitreal injection combined with retinal laser photocoagulation therapy and simple laser photocoagulation treatment of macular edema secondary to retinal vein occlusion are both effective that macular edema is significantly reduced, and vision is stable and improved. But for serious cases, conbercept intravitreal injection can reduce retinal edema at first, then combine with retinal laser photocoagulation which has obvious therapeutic effect and it is better than simple laser photocoagulation treatment.

    参考文献
    相似文献
    引证文献
引用本文

刘慧峰,贾俊,姬明利,等.康柏西普联合激光治疗视网膜静脉阻塞继发黄斑水肿.国际眼科杂志, 2017,17(11):2140-2143.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
  • HTML阅读次数:
  • 引用次数:
历史
  • 收稿日期:2017-05-10
  • 最后修改日期:2017-09-22
  • 录用日期:
  • 在线发布日期: 2017-10-19
  • 出版日期: